Surrozen, Inc.
171 Oyster Point Boulevard
Suite 400
South San Francisco
California
94080
United States
Tel: 650-475-2820
Website: http://surrozen.com/
About Surrozen, Inc.
Repair. Restore. Renew
Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway. Surrozen is at pre-clinical stage, and anticipates its first clinical trials will be underway in 2022. Surrozen (SRZN) became publicly traded in August of 2021.
Culture
Our inclusive and pioneering culture creates a sense of belonging, impact, adventure and fun. Join us and Collaborate, Lead, Innovate Motivate and be Brave, Open and Nurturing at Surrozen!
Total Rewards
Surrozen offers a competitive total rewards package that includes:
- Health and welfare benefits
- Generous vacation, sick leave, and company paid holidays
- 401k match
- Company sponsored events, adventures and weekly lunches
- Bring your dog to work Fridays
Craig Parker is the Chief Executive Officer at Surrozen. Their research in the Wnt pathway and proteins identified these are critical to maintaining tissues in our body and are found in tissues as diverse as the lung, intestine, liver, sensory hair cells, and the eye.
New Company Values
A committee of Surrozen employees put their heads together and came up with our new company values. In every project we take on these 7 keys words are at the forefront. CLIMB ON!!!
39 articles with Surrozen, Inc.
-
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis
5/18/2022
Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first subject has been dosed in its three-part Phase 1 clinical trial.
-
Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of IBD
5/16/2022
Surrozen, Inc. announced the publication of an article by Surrozen scientists in the journal Cellular and Molecular Gastroenterology and Hepatology.
-
Surrozen Reports First Quarter 2022 Financial Results
5/11/2022
Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the first quarter of 2022 and provided a corporate update.
-
Surrozen to Present at the BofA Securities 2022 Healthcare Conference
5/5/2022
Surrozen, Inc. today announced that Craig Parker, President and Chief Executive Officer, will present at the BofA Securities 2022 Healthcare Conference at 4 p.m. PT on Wednesday, May 11.
-
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
5/2/2022
Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that a poster supporting the potential of SZN-413 for the treatment of diabetic retinopathy was presented on May 1 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver.
-
Surrozen Reports Fourth Quarter and Full Year 2021 Financial ResultsOn Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of 2022
3/24/2022
Surrozen, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
-
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline
1/10/2022
Surrozen, Inc., a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced key development goals and acceleration of its research pipeline as the company transitions to a clinical-stage biotechnology company.
-
Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present virtually on January 13, 2022 at 9 a.m. ET, at the 40th J.P. Morgan Healthcare Conference.
-
Surrozen's ethos is “CLIMB ON”. This catchy and focus-appropriate acronym stands for Collaborate, Lead, Innovate, Motivate and be Brave, Open and Nurturing.
-
Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
11/15/2021
Surrozen, Inc. today announced that Craig Parker, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 22.
-
Surrozen Reports Third Quarter 2021 Financial Results
11/15/2021
Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
-
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
11/15/2021
Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that data from its liver disease program, including preclinical studies of SZN-043 showing improved liver metabolic function, were presented during The Liver Meeting 2021.
-
Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference
11/5/2021
Surrozen, Inc. today announced that Craig Parker, Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference at 4:40 p.m. ET on Tuesday, November 16.
-
Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week
10/5/2021
Surrozen, Inc. announced that data from its inflammatory bowel disease program, including preclinical studies of SZN-1326 showing colonic mucosal healing in an acute injury model were presented during the 2021 United European Gastroenterology Week.
-
Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources
9/23/2021
Surrozen Inc. today announced that Elizabeth “Liz” Nguyen has been appointed as Vice President and Head of Human Resources (HR).
-
Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration
8/11/2021
Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced the completion of its business combination with Consonance-HFW Acquisition Corp., a special purpose acquisition company sponsored by entities affiliated with Consonance Capital Management.
-
Surrozen to Present at Canaccord Genuity’s 41st Annual Growth Conference
8/5/2021
Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced that Craig Parker, chief executive officer, will provide a company overview and a business update at Canaccord Genuity’s 41st Annual Growth Conference at 9:30 a.m. ET on Thursday, August 12.
-
Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organization
7/9/2021
Surrozen Inc. announced today that new data from its inflammatory bowel disease (IBD) program, including preclinical studies of SZN-1326 showing superior activity compared to therapeutics currently used in treatment, were presented during the 16 th Congress of the European Crohn’s and Colitis Organisation.
-
Surrozen Presents Data at 2021 International Liver Conference for Wnt-Modulating Antibody SZN-043Company to advance SZN-043 toward first-in-human clinical studies in 2022
6/25/2021
Surrozen Inc. announced today that data from preclinical studies of SZN-043 were presented during The Digital International Liver Congress™ 2021 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL).
-
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference: Fundamental Mechanisms and Translational Applications
6/17/2021
Surrozen Inc. announced today that data from preclinical studies were presented in four oral Abstract Flash Talk presentations during The Liver Biology Conference.